Publications
Than MT, Dequiedt L, Sor R, Nair S, Markosyan N, Furth EE, Yang C, Ray-Fofana C, Menard M, Quintana E, Edwards AC, Hennessey CJ, Good AL, Quinones L, Hwang Y, Clendenin C, Kiemen AL, Vonderheide RH, Stanger BZ Cancer interception with KRAS inhibitors in preclinical models of pancreatic ductal adenocarcinoma , Science, 391(6790): 2026,1161-1166
Mo F, Good AL, McDevitt JC, Dang H, Engle DD, Posey AD Jr, Stanger BZ The CA19-9 glycan is a viable target for CAR T cell therapy in pancreatic and other solid tumors , Gastroenterology: 2026
Orlen MI, Vostrejs WP, Sor R, McDevitt JC, Kemp SB, Kim IK, Kramer AB, Tovbis Shifrin N, Markosyan N, Clendenin C, Singh M, Quintana E, Menard M, Vonderheide RH, Stanger BZ T-cell dependency of tumor regressions and complete responses with RAS(ON) multi-selective inhibition in preclinical models of PDAC , Cancer Discov, 15(8): 2025,1697-1716
Kahn BM, Ng RWS, Kim IK, Eskandarian C, Chen CO, Huang B, Lucas A, Li L, Maillard I, Stanger BZ Intrinsic properties of the lymph node render it immunologically susceptible to metastasis , Cancer Discov, 15(9): 2025,1949-1968
Katsuda T, Sussman JH, Ito K, Katznelson A, Yuan S, Takenaka N, Li J, Merrell AJ, Cure H, Li Q, Rasool RU, Asangani IA, Zaret KS, Stanger BZ Cellular reprogramming in vivo initiated by SOX4 pioneer factor activity , Nat Commun, 15(1): 2024,1761
Kim I-K, Diamond MS, Yuan S, Kemp SB, Kahn BM, Li Q, Lin JH, Li J, Norgard RJ, Thomas SK, Merolle M, Katsuda T, Tobias JW, Baslan T, Politi K, Vonderheide RH, Stanger BZ Plasticity-induced repression of Irf6 underlies acquired resistance to cancer immunotherapy in pancreatic ductal adenocarcinoma , Nat Commun, 15(1): 2024,1532
Li J, Stanger BZ The tumor as organizer model , Science, 363(6431): 2019,1038-1039
Ben Stanger From One Cell: A Journey into Life's Origins and the Future of Medicine , W.W. Norton: 2023
